LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 21.81M | — | $19.75B | 3.2% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 19.62M | — | $17.76B | 12.9% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasivo) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasivo) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (pasivo) | 11.00M | — | $9.96B | 1.5% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 16 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 4.89M | — | $4.43B | 1.9% | n/c | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.61M | — | $1.46B | 1.3% | n/c | 1 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 930.00K | — | $842.00M | 3.9% | n/c | 1 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 827.68K | — | $749.37M | 1.4% | n/c | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ |
| 24 | Millennium Management ✦ | 532.04K | — | $481.70M | 0.4% | n/c | 1 | SEC ↗ |
| 25 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ |
| 26 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 31 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ |
| 32 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ |
| 33 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ |
| 34 | Two Sigma Investments ✦ | 225.78K | — | $204.42M | 0.5% | n/c | 1 | SEC ↗ |
| 35 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 36 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 37 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 38 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ |
| 39 | Viking Global Investors ✦ | 144.18K | — | $130.53M | 0.5% | n/c | 1 | SEC ↗ |
| 40 | Bridgewater Associates ✦ | 95.74K | — | $86.68M | 0.5% | n/c | 1 | SEC ↗ |
| 41 | Dodge & Cox ✦ | 45.98K | — | $41.63M | 0.0% | n/c | 1 | SEC ↗ |
| 42 | GAMCO Investors ✦ | 35.83K | — | $32.44M | 0.4% | n/c | 1 | SEC ↗ |
| 43 | Gotham Asset Management ✦ | 11.95K | — | $10.82M | 0.1% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 4,323 tenedores, 762.84M acciones, $674.93B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 6.50K acc. · $7.64M
Officer · 2.00K acc. · $2.37M
Officer · 5.00K acc. · $5.95M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
Forbes